DR. AZZAM ZIADE MD
- Medical Oncology
- Hematology Oncology
Dr. Azzam Ziade obtained national diploma in Medical Oncology from university of Padova in 1999. (The training of medical oncology was under the patronage Prof. Bona Donna-Leader in Medical Oncology). He followed the school of clinical hematology led by Prof. Lucarelli (Leader in the world for Bone marrow transplantation in thalassemia) with master degree in bone marrow transplant in 2003. After that, he started the program of M.R.C Path at Kings College hospital � London in Clinical Hematology department from 2008 to 2012 under the patronage of Prof. Mufti (Leader in Myelodysplastic Syndrome). In 2012 he worked at the University hospital of Rafeik Hariri in Beirut-Lebanon as head of department of Bone Marrow transplant and Oncology-Hematology department. He is expert in Thalassemia and Sickle cell anemia Bone Marrow Transplantation. Extensive knowledge relative to hematological diseases (Benign and Malignant), haemoglobinopathy, haemostatic disorders, haemophilia and solid tumours.
- Collaborated to 10 Congressional abstract and 3 articles
- Full dose (FD) Chemotherapy (CT) plus Lenogastrim and Low Dose (LD) CT in Elderly patients with small cell lung cancer. A Phase II randomised FONICAP-GSTV study.
- Chemo-Radiotherapy in Elderly and/or poor performance status patients with advanced Head and Neck and oesophageal cancer.
- Simultaneous carcinomas of the Ovary and Endometrium (S.C.O.E)
- Increase in weight in Breast cancer patient during adjuvant chemo and hormonal therapy.
- CPT-11 and 5-Flourouracil in pre-treated patients with metastatic colorectal cancer.
- Preoperative chemo-radiotherapy in respectable rectal cancer.
- Weekly Docetaxel for metastatic Breast cancer (MBC): A Phase II trial.
- Enhancement of local control in locally advanced node-positive Naso-pharyngeal carcinoma by continued chemo-radiotherapy.
- Oxaliplatin: A new drug for the treatment of colorectal cancer.
- Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast cancer (Tumori 2001 Jul-Aug; 87 (4):223-8).
- Intralesional Topotecan in Advanced Ovarian cancer: A Clinical report, based on a preclinical study (Oncology Reports 9: 1351-1354, 2002).
- Delayed initiation of front-line Imatinib therapy predicts for poor response to Nilotinib as second-line treatment of Imatinib resistant or intolerant CML: single Center report for the ENACT in Lebanon. International journal of Hematology 09/2012;96(4): 521-4. 1.17 impact factor.